X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaborations aim to support NRx for the development of NRX-101 (D-cycloserine) in the treatment of bipolar depression with suicidality.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: NRx Pharmaceuticals
Deal Size: $345.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration February 11, 2024
Details:
Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.
Lead Product(s): Lisinopril
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Zestril
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: TWi Pharmaceuticals, Inc.
Deal Size: $38.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 18, 2023
Details:
XIFAXAN (rifaximin) 200 mg tablets are indicated for travelers diarrhea. XIFAXAN (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea in adults.
Lead Product(s): Rifaximin
Therapeutic Area: Gastroenterology Product Name: Xifaxan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
XIFAXAN (rifaximin) is a 2 week prescription treatment that provided up to 6 months of relief from IBS-D symptoms of abdominal pain and diarrhea in a clinical trial.
Lead Product(s): Rifaximin
Therapeutic Area: Gastroenterology Product Name: Rifaximin-Generic
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Belbuca
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: BioDelivery Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021
Details:
Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.
Lead Product(s): Lisinopril
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Zestril
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AZTIQ PHARMA
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 30, 2021
Details:
Luye Pharma granted Alvogen Korea, Zuellig Pharma and DKSH exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hong Kong and Thailand.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Luye Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
